Ruxolitinib, a JAK1/2 inhibitor reduces the number of circulating activated T cells in patients with cGVHD [32], was prospectively evaluated in a phase III randomized study including children who had glucocorticoid-refractory acute GVHD after HSCT [33]. The gene discussed is JAK1; the disease is acute graft versus host disease.